SMC Laboratories Abstract Accepted for WCN 2026
We are pleased to announce that our abstract has been accepted for poster presentation at the ISN World Congress of Nephrology 2026 (WCN’26), to be held in Yokohama from March 28–31, 2026.
Abstract No.
WCN26-AB-6275
Title
Single-Agent Treatment with an ALK5 Inhibitor or an SGLT2 Inhibitor (Dapagliflozin) Attenuates Renal Fibrosis in the UUO Mouse Model
This study demonstrates that both an ALK5 inhibitor and the SGLT2 inhibitor dapagliflozin attenuate renal fibrosis in the UUO mouse model.
We will continue advancing high-quality preclinical research to support the development of innovative therapies in kidney disease.